Ongoing treatment(s)-Chemotherapy Page 2 Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Chemotherapy Posts on Medivizor

Evaluating Cetuximab plus FOLFOX-4 chemotherapy for patients with metastatic colorectal cancer

Posted by on Oct 13, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of cetuximab (Erbitux) combined with FOLFOX-4 (leucovorin, fluorouracil, and oxaliplatin) chemotherapy to treat metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that this treatment is associated with improved cancer outcomes. Some background...

Read More

Lenalidomide consolidation therapy for patients receiving chemoimmunotherapy for chronic lymphocytic leukemia

Posted by on Sep 18, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of lenalidomide consolidation therapy after chemoimmunotherapy for patients with chronic lymphocytic leukemia. This study concluded that this regimen improves outcomes for these patients. Some background Fludarabine (Fludara) is a chemotherapy used for the treatment of chronic lymphocytic...

Read More

Comparing chemoimmunotherapy and ibrutinib treatment in patients with chronic lymphocytic leukemia

Posted by on Sep 7, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of patients with chronic lymphocytic leukemia who received chemoimmunotherapy or ibrutinib. This study suggested that ibrutinib may have more favorable outcomes for these patients when compared to chemoimmunotherapy. Some background Chemoimmunotherapy (CIT) is a treatment option that can be used...

Read More

Is a low-intensity chemotherapy treatment plan safe and effective for elderly patients with Acute Myeloid Leukemia?

Posted by on Sep 6, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to create a safe and effective low-intensity chemotherapy treatment plan for elderly patients with AML . This is an ongoing clinical trial and so far the authors have found the therapy has been safe and effective. Some background Outcomes for elderly patients with AML in the past have not been good due to the high...

Read More

Evaluating rituximab maintenance therapy in patients with newly diagnosed follicular lymphoma

Posted by on Sep 6, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...

Read More

Evaluating the outcomes after second-line therapy for relapsed or refractory PMBCL

Posted by on Aug 17, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the outcomes of pretreated patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) primary mediastinal large B-cell lymphoma (PMBCL) after second-line therapy and stem cell transplant (SCT). The study concluded that this treatment strategy was effective in most patients. Some...

Read More

Evaluating venetoclax with BR for the treatment of relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Aug 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...

Read More

Comparing obinutuzumab and rituximab in first-line chemotherapy regimens for follicular lymphoma

Posted by on Jul 2, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of obinutuzumab (Gazyva) versus rituximab (Rituxan) plus chemotherapy for previously untreated follicular lymphoma. This study concluded that obinutuzumab improved survival outcomes compared to rituximab. Some background Follicular lymphoma is the most common type of...

Read More

Does 8 cycles of R-CHOP lead to better survival than 6 cycles for diffuse large B-cell lymphoma?

Posted by on Jun 21, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined whether 6 or 8 cycles of R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy led to better survival outcomes in patients with newly diagnosed diffuse large B-cell lymphoma. This study concluded that outcomes following 6 or 8 cycles of R-CHOP-21 are similar for these patients. Some...

Read More